寡转移前列腺癌的临床处理策略

doi:10.6040/j.issn.1671-7554.0.2018.1151

摘要/Abstract

摘要： 寡转移前列腺癌可能是前列腺癌进展的特殊阶段,对其进行积极的处理可能取得良好的疗效。但目前仍认识不足且存在较大争议。就寡转移前列腺癌的定义、诊断和处理进行综述。

关键词: 前列腺癌, 寡转移, 减瘤性根治性切除术, 转移灶进行转移导向治疗

Abstract: Oligometastatic prostate cancer may be a special stage of prostate cancer progression. Positive treatment of oligometastatic prostate cancer may achieve good results. However, there is still a lack of understanding and controversy about it. This article reviews the definition, diagnosis and management of oligometastatic prostate cancer.

Key words: Prostate cancer, Oligometastatic, Cytoreductive radical prostatectomy, Metastasis-directed therapy

中图分类号:

R737

韩邦旻,荆翌峰. 寡转移前列腺癌的临床处理策略[J]. 山东大学学报 (医学版), 2019, 57(1): 26-29.

HAN Bangmin, JING Yifeng. Clinical management of oligometastatic prostate cancer[J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 26-29.

参考文献

[1] Hellman S, Weichselbaum RR. Oligometastases[J]. J Clin Oncol, 1995, 13(1): 8-10.
[2] Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC, 2017[J]. Eur Urol, 2018, 73(2): 178-211.
[3] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2017, 71(4): 618-629.
[4] deSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group[J]. Eur J Cancer, 2018, 91: 153-163. doi:10.1016/j.ejca.2017.12.012.
[5] Clement JM, Sweeney CJ. Evolving treatment of oligometastatic hormone-sensitive prostate cancer[J]. J Oncol Pract, 2017, 13(1): 9-18.
[6] Löfgren J, Mortensen J, Rasmussen SH, et al. A prospective study comparing ^99mTc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with ¹⁸F-fluoride PET/CT and ¹⁸F-fluoride PET/MRI for diagnosing bone metastases[J]. J Nucl Med, 2017, 58(11): 1778-1785.
[7] Hövels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis[J]. Clin Radiol, 2008, 63(4): 387-395.
[8] Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer[J]. Theranostics, 2012, 2(3): 318-330.
[9] Fendler WP, Calais J, Allen-Auerbach M, et al.⁶⁸Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study[J]. J Nucl Med, 2017, 58(10): 1617-1623.
[10] Corfield J, Perera M, Bolton D, et al. ⁶⁸Ga-prostate specific membrane antigen(PSMA)positron emission tomography(PET)for primary staging of high-risk prostate cancer: a systematic review[J]. World J Urol, 2018, 36(4): 519-527.
[11] Zattoni F, Zattoni F, Evangelista L. Re: marlon perera, nathan papa, daniel christidis, et al. sensitivity, specificity, and predictors of positive ⁶⁸Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016; 70: 926-37[J]. Eur Urol, 2017, 71(2): e64-e65. doi:10.1016/j.eururo.2016.08.049.
[12] von Eyben FE, Picchio M, von Eyben R, et al. ⁶⁸Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis[J]. Eur Urol Focus, 2018, 4(5): 686-693.
[13] Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease[J]. J Urol, 2002, 168(3): 1008-1012.
[14] Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry[J]. Eur Urol, 2014, 66(3): 602-603.
[15] Bayne CE. Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65: 1058-66[J]. Eur Urol, 2014, 65(6): e99. doi:10.1016/j.eururo.2013.12.060.
[16] Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study[J]. J Urol, 2015, 193(3): 832-838.
[17] Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation[J]. European Urology, 2016, 69(5): 788-794.
[18] Gandaglia G, Fossati N, Stabile A, et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up[J]. Eur Urol, 2017, 72(2): 289-292.
[19] Wiegand LR, Hernandez M, Pisters LL, et al. Surgical management of lymph-node-positive prostate cancer: improves symptomatic control[J]. BJU Int, 2011, 107(8): 1238-1242.
[20] Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer[J]. BJU Int, 2013, 112(4): E250-E255. doi:10.1111/bju.12169.
[21] Jereczek-Fossa BA, Fariselli L, Beltramo G, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer[J]. Radiother Oncol, 2009, 93(1): 14-17.
[22] Muacevic A, Kufeld M, Rist C, et al. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer[J]. Urol Oncol, 2013, 31(4): 455-460.
[23] Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer[J]. Front Oncol, 2012, 2: 215. doi:10.3389/fonc.2012.00215.
[24] Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy[J]. Clin Genitourin Cancer, 2013, 11(1): 27-32.
[25] Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence[J]. Radiat Oncol, 2014, 9: 135. doi:10.1186/1748-717X-9-135.
[26] Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial[J]. J Clin Oncol, 2018, 36(5): 446-453.
[27] Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy(SABR)for oligometastatic prostate cancer: a prospective clinical trial[J]. Eur Urol, 2018, 74(4): 455-462.
[28] Oertel M, Scobioala S, Kroeger K, et al. Worth a local treatment? -Analysis of modern radiotherapy concepts for oligometastatic prostate cancer[J]. Radiat Oncol, 2018, 13: 185. doi:10.1186/s13014-018-1118-7.
[29] Cattrini C, Zanardi E, Boccardo F. Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer[J]. J Clin Oncol, 2018, 36(22): 2350. doi:10.1200/JCO.2018.78.0031.

相关文章 15

[1]	许振,刁统祥,臧振杰,邵丁昌,张奇,孙鼎琪,傅强. 前列腺特异性抗原同源异构体2及其衍生指标在前列腺癌诊断中的价值[J]. 山东大学学报 (医学版), 2022, 60(6): 51-56.
[2]	孙浩瑜,姜鑫,陈守臻,曲思凤,史本康. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(6): 46-50.
[3]	史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[4]	徐兵,李勇,刘明,刘永辉. 沉默PRRX1基因表达可增强前列腺癌耐药细胞株PC-3/DTX对多西他赛的敏感性[J]. 山东大学学报 (医学版), 2021, 59(6): 103-110.
[5]	孙鼎琪,傅强,张辉,刘帅,刁统祥,曹庆伟,张克勤. 多参数磁共振与经直肠超声融合前列腺靶向穿刺活检在检测PI-RADS≥3前列腺癌中的临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 108-113.
[6]	朱刚,张凯. 中国前列腺癌筛查的现状和挑战[J]. 山东大学学报 (医学版), 2019, 57(1): 11-15.
[7]	周芳坚,黄华,李永红. 前列腺癌的局灶冷冻治疗[J]. 山东大学学报 (医学版), 2019, 57(1): 6-10.
[8]	吕家驹,胡佳林,丁森泰. 前列腺癌局部治疗的研究进展[J]. 山东大学学报 (医学版), 2019, 57(1): 1-5.
[9]	姚旭东. 局部晚期前列腺癌手术治疗策略及疗效[J]. 山东大学学报 (医学版), 2019, 57(1): 21-25.
[10]	翟红运, 张登禄, 王光杰, 孔峰, 程广辉, 赵升田. 小鼠胚胎干细胞分泌因子对前列腺癌细胞作用的体外研究[J]. 山东大学学报（医学版）, 2015, 53(9): 8-12.
[11]	丁焕1，孙颖1，黎晓晴2，黎莉1. PARP抑制剂联合吉西他滨或多西他赛对雄激素非依赖性前列腺癌PC3细胞增殖的影响[J]. 山东大学学报（医学版）, 2014, 52(1): 33-36.
[12]	高逢彬，司曼飞，刘永青，牛蕾蕾，苑辉卿. 网脊衣酸上调p21CIP1蛋白诱导前列腺癌细胞周期阻滞的作用分析[J]. 山东大学学报(医学版), 2013, 51(12): 34-40.
[13]	于张健1，张士宝1，刘庆勇1，阮喜云2，杨广笑3，王全颖3. SAC重组腺相关病毒载体的构建及其对前列腺癌CAM移植瘤的抑制作用[J]. 山东大学学报(医学版), 2012, 50(7): 41-.
[14]	许爱辉1，潘喆2，蒋汉明1，孔峰1，胡志敏3，苑辉卿1. 地前素M抗前列腺肿瘤活性的初步探讨[J]. 山东大学学报(医学版), 2010, 48(5): 18-22.
[15]	陈卫国1，龙慧民2，侯建全1，浦金贤1，严春寅1. Gefitinib对激素非依赖性前列腺癌的治疗及其效应初探[J]. 山东大学学报(医学版), 2010, 48(1): 52-55.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed